Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Summary

The goal of this clinical research study is to learn if the study drug RAD001 can stop or slow the growth of resectable soft tissue sarcoma. The patient's physical state, their symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if RAD001 is safe and effective in patients with this condition. The study drug, RAD001, is made by Novartis Pharmaceuticals Corporation.

Timeline

Start

2010-01

Primary completion

2011-10

Completion

2011-10

Outcome

Outcome not reported

Stopped (Business): “Novartis terminated funding”

Drugs

Indications